% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Jun 10, 2014 7:26 AM Flag

    European update on ASCO studies ( this am)


    Multiple studies presented at 2014 ASCO annual meeting reinforce unique, practice-changing value of Oncotype DX® breast cancer test
    Demonstrate importance of consistent results from multiple validation studies
    Highlight substantial differences between multi-gene tests
    Reinforce Genomic Healthâ#$%$™s commitment to improving the quality of treatment decisions for cancer patients
    GENEVA, Switzerland--(BUSINESS WIRE)-- Genomic Health, Inc. (Nasdaq: GHDX) announced results of three studies with the Oncotype DX breast cancer test at the recent 2014 American Society of Clinical Oncology® (ASCO®) Annual Meeting.

    This topic is deleted.
29.910.00(0.00%)Oct 26 4:00 PMEDT